96.02

0.80% -0.79

After Hours: 96.09 0.07 +0.07%

Abbott Laboratories (ABT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Abbott Laboratories stock is traded at $96.02, with a volume of 6.65M. It is down -0.80% in the last 24 hours and down -8.93% over the past month. Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.

Previous Close:

$96.81

Open:

$96.5

24h Volume:

6.65M

Relative Volume:

0.55

Market Cap:

$166.85B

Revenue:

$45.13B

Net Income/Loss:

$6.28B

P/E Ratio:

26.75

EPS:

3.5895

Net Cash Flow:

$7.40B

1W Performance:

-4.62%

1M Performance:

-8.93%

6M Performance:

-25.85%

1Y Performance:

-26.68%

1-Day Range:

$95.49

$97.32

1-Week Range:

$93.92

$102.48

52-Week Range:

$93.92

$139.06

Abbott Laboratories Stock (ABT) Company Profile

Name

Abbott Laboratories

Sector

Healthcare (1119)

Industry

Medical Devices (142)

Phone

(224) 667-6100

Address

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Employee

115,000

Twitter

@AbbottNews

Next Earnings Date

2026-04-16

Latest SEC Filings

ABT's Discussions on Twitter

Compare ABT vs SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABT Abbott Laboratories	96.02	168.22B	45.13B	6.28B	7.40B	3.5895
SYK Stryker Corp	338.35	131.49B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	85.00	110.66B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	60.99	95.46B	20.08B	2.89B	3.66B	1.9391
EW Edwards Lifesciences Corp	81.44	46.69B	6.07B	1.06B	1.34B	1.8063

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Initiated	The Benchmark Company	Buy
Jul-18-25	Upgrade	Jefferies	Hold → Buy
Jun-16-25	Initiated	Leerink Partners	Market Perform
Oct-08-24	Initiated	Oppenheimer	Outperform
Sep-19-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Downgrade	Edward Jones	Buy → Hold
May-30-24	Initiated	Goldman	Buy
Jul-21-23	Upgrade	Wolfe Research	Underperform → Peer Perform
May-30-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-23	Reiterated	Barclays	Overweight
Apr-20-23	Reiterated	Bernstein	Outperform
Apr-20-23	Reiterated	JP Morgan	Overweight
Apr-20-23	Reiterated	Raymond James	Outperform
Apr-20-23	Reiterated	UBS	Buy
Apr-20-23	Reiterated	Wolfe Research	Underperform
Mar-29-23	Initiated	UBS	Buy
Oct-26-22	Initiated	Mizuho	Neutral
Oct-18-22	Initiated	Barclays	Overweight
Oct-12-22	Initiated	Jefferies	Hold
Jul-06-22	Initiated	Wolfe Research	Underperform
Mar-02-22	Resumed	BofA Securities	Buy
Jan-27-22	Reiterated	Credit Suisse	Outperform
Jan-27-22	Reiterated	Morgan Stanley	Overweight
Jan-27-22	Reiterated	Raymond James	Outperform
Jan-27-22	Reiterated	UBS	Buy
Dec-10-21	Initiated	RBC Capital Mkts	Outperform
Oct-27-21	Upgrade	Atlantic Equities	Neutral → Overweight
Oct-14-21	Initiated	Redburn	Neutral
May-25-21	Initiated	Barclays	Overweight
Apr-15-21	Initiated	Atlantic Equities	Neutral
Jan-28-21	Upgrade	BTIG Research	Neutral → Buy
Sep-11-20	Initiated	Wolfe Research	Outperform
Jun-01-20	Downgrade	Goldman	Neutral → Sell
Mar-05-20	Initiated	Citigroup	Buy
Feb-13-20	Initiated	Goldman	Neutral
Feb-06-20	Resumed	BTIG Research	Neutral
Jan-02-20	Downgrade	Guggenheim	Buy → Neutral
Jun-13-19	Reiterated	BofA/Merrill	Buy
Feb-07-19	Reiterated	BofA/Merrill	Buy
Jan-02-19	Downgrade	Citigroup	Neutral → Sell
Nov-30-18	Upgrade	Goldman	Neutral → Buy
Oct-16-18	Initiated	Barclays	Overweight
Jun-27-18	Initiated	Bernstein	Outperform
Jan-30-18	Reiterated	Citigroup	Neutral
Jan-25-18	Reiterated	Stifel	Buy
Jan-25-18	Upgrade	William Blair	Mkt Perform → Outperform
Jan-03-18	Initiated	Evercore ISI	Outperform
Jan-02-18	Upgrade	JP Morgan	Neutral → Overweight
Jan-02-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-19-17	Reiterated	RBC Capital Mkts	Outperform
Oct-19-17	Reiterated	Stifel	Buy

View All

Abbott Laboratories Stock (ABT) Latest News

01:10 AM

Abbott Wins Glucose Monitor Sales Ban On Appeal At UPC - Law360

01:10 AM

12:00 PM

SCS Injury Lawsuit Alleges Unlicensed Abbott Representatives Modified Device After Implantation - AboutLawsuits.com

12:00 PM

11:09 AM

Abbott Laboratories Stock (ABT) Opinions on Q1 Earnings and Guidance Cut - Quiver Quantitative

11:09 AM

09:45 AM

Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS

09:45 AM

08:18 AM

Bernstein SocGen cuts Abbott Labs stock price target on weak quarter - Investing.com Canada

08:18 AM

07:05 AM

Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - 24/7 Wall St.

07:05 AM

05:53 AM

Abbott price target lowered to $143 from $144 at Barclays - TipRanks

05:53 AM

05:08 AM

Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount - The Motley Fool

05:08 AM

Apr 19, 2026

Intuitive Surgical (ISRG) Q1 Earnings: What To Expect - TradingView

Apr 19, 2026

Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to drive sustained growth f - AD HOC NEWS

Apr 19, 2026

Abbott Laboratories in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q1; nutrition falls - MSN

Apr 19, 2026

Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN

Apr 19, 2026

Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st

Apr 19, 2026

ABT: Abbott Laboratories Lowers Earnings Outlook Despite Revenue Beat - GuruFocus

Apr 19, 2026

Apr 18, 2026

How Abbott is Changing the Way We Treat AFib - Tomorrow's World Today

Apr 18, 2026